-
Uncategorized2 months agoFauci adviser David Morens indicted for concealing emails, avoiding records requests
WASHINGTON — David Morens, a former top National Institute of Allergy and Infectious Diseases official, was indicted Tuesday on allegations that he concealed records from Freedom...
-
Uncategorized2 months ago‘Type’ Casting: Flagship-Founded Serif Modifying DNA into New Therapy Class
What happens when the scalability and redosability of messenger RNA (mRNA) is combined with the durability and programmability of gene therapy? According to Serif Biomedicines, a...
-
Uncategorized2 months agoPfizer deals extend patent life for a top-selling rare disease drug
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
-
Uncategorized2 months agoBoehringer dual-acting obesity shot hits mark in Phase 3 trial
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well. Read More
-
Uncategorized2 months ago
Prostate Cancer Therapy Targets Disordered Region of Androgen Receptor
In a new study published in Nature Signal Transduction and Targeted Therapy titled, “Drugging the intrinsically disordered transactivation domain of androgen receptor,” researchers from the University of British...
-
Uncategorized2 months ago
Rocket’s PRV goes for $180M; Oruka targets $500M offering
Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got...
-
Uncategorized2 months ago
AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B
AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for the oral...
-
Uncategorized2 months ago
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts...
-
Uncategorized2 months ago
FDA flags concerns for AstraZeneca’s camizestrant, Truqap ahead of advisory committee meeting
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead of an upcoming advisory committee meeting, the first such...
-
Uncategorized2 months agoFDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold...
STAT+: Pharmalittle: We’re reading about Pfizer’s emergency penicillin program, a Sanofi diabetes drug, and more
